Leadership

MUSC Hollings Cancer Center is led by a team of renowned physicians, researchers, and administrators who have trained and served in prominent positions at some of the country’s top cancer centers and academic medical institutions. These leaders provide vision, guidance, and expertise across all of the center’s programs and initiatives.

Hollings also benefits from an external Advisory Board comprised of business, government, and lay community leaders as well as an External Scientific Advisory Board (ESAB) consisting of nationally-recognized leaders in cancer research and treatment. Together, these teams are charged with establishing Hollings as one of the country’s top centers for cancer care.

Center Director

Dr. Raymond DuBois wearing a white physician's coat

Raymond N. DuBois, M.D., Ph.D.

duboisrn@musc.edu
Hollings Cancer Center 124J

Dr. DuBois began his appointment as director of MUSC Hollings Cancer Center in August 2020. As a physician-scientist, Dr. DuBois is passionate about cancer research and patient-centered care, and his expertise guides Hollings forward in both areas.

An international leader in the cancer community, Dr. DuBois has more than 30 years of research experience and over 20 years of concurrent leadership experience, including senior roles at MD Anderson Cancer Center and Vanderbilt-Ingram Cancer Center. He was elected to the National Academy of Medicine in 2019, which places him in the company of an elite group of internationally renowned scientists and doctors.

Center Leadership

Dr. Marvella Ford

Marvella E. Ford, Ph.D.

Associate Director, Population Science and Cancer Disparities

fordmar@musc.edu
Bioengineering 103A

A professor of public health sciences, Dr. Ford oversees the center’s effort to address the state’s critical cancer disparities while implementing initiatives that integrate expertise in population sciences among the center’s cancer control researchers. Through community outreach and educational programs, Dr. Ford and her team work with minority leaders throughout the state to build bi-directional, trusting, and long-lasting partnerships, which are critical to Hollings investigators in tailoring culturally and contextually knowledgeable cancer interventions. She also works with the South Carolina Department of Health and Environmental Control to implement cancer-focused initiatives, including the State Cancer Plan.

 

Dr. Denis Guttridge

Denis C. Guttridge, Ph.D.

Associate Director, Translational Science

guttridg@musc.edu
Drug Discovery 305

Dr. Guttridge joined MUSC in 2018 as the Hollings Cancer Center associate director of translational science and the director of the Charles P. Darby Children’s Research Institute. Dr. Guttridge holds a robust research funding portfolio and has authored more than 130 peer-reviewed publications. He has received numerous recognitions for his contributions to cancer research and his dedication to fostering multidisciplinary and collaborative science.

 

Dr. Sara Hook

Sara Hook, Ph.D.

Executive Director of Research Administration and Chief Administrative Officer

hooksar@musc.edu
Hollings Cancer Center 124G

Dr. Hook joined Hollings as the executive director of research administration and chief administrative officer in 2022. In her role, Dr. Hook works closely with the director and members of senior and programmatic leadership to build and support the research infrastructure crucial to Hollings’ mission. She identifies new cancer research opportunities and develops resources to support these and existing efforts. Dr. Hook previously served as the National Cancer Institute’s Associate Director for Strategic Scientific Partnerships.

 

Dr. Craig Lockhart

Craig Lockhart, M.D.

Associate Director, Clinical Science
Chief, Oncology Integrated Center of Clinical Excellence

lockhara@musc.edu

Dr. Lockhart is the chief of the Division of Hematology & Oncology in the MUSC Department of Medicine. With over 20 years of experience conducting clinical trials, a key part of his role as associate director is facilitating efforts to bring scientific discoveries from Hollings' laboratories into clinical application through clinical trials. As the Oncology Integrated Center of Clinical Excellence (ICCE) chief, Dr. Lockhart oversees the clinical activities and performance of Hollings and executes strategies for program development and growth.

 

Dr. Besim Ogretmen

Besim Ogretmen, Ph.D.

Associate Director, Basic Science

ogretmen@musc.edu
Hollings Cancer Center 512

Dr. Ogretmen is a professor of Biochemistry and Molecular Biology and the SmartState Endowed Chair of Lipidomics and Drug Discovery. An internationally renowned investigator, Dr. Ogretmen has over 25 years of experience in cancer research, specializing in the field of lipid signaling and metabolism. In this associate director role, Dr. Ogretmen integrates fundamental discoveries across multiple discipline areas, helping to accelerate translational advances into the clinic. His overall goal is to improve survival outcomes of cancer patients by developing collaborative/team science-based research projects between basic and clinical researchers.

 

Dr. Steven Rosenzweig

Steven A. Rosenzweig, Ph.D.

Associate Director, Shared Resources

rosenzsa@musc.edu
Basic Sciences 313G

Dr. Rosenzweig is a professor of cell and molecular pharmacology. As associate director, he oversees the ongoing evaluation, development, and growth of Hollings-supported shared research resources. These shared facilities provide access to critical technologies, services, and consultation that enhance scientific interaction and productivity of cancer center members.

 

Dr. Nicholas Shungu

Nicholas Shungu, M.D.

Associate Director, Diversity, Equity and Inclusion

shungu@musc.edu

Dr. Shungu, a family medicine doctor, sees the impact of cancer disparities first-hand in the patients he treats. As associate director, he leads efforts to infuse diversity, equity and inclusion into patient care, research, education and staff recruitment. He also supports Hollings initiatives to reduce cancer disparities across the state and increase minority enrollment in clinical trials.

 

Dr. Benjamin Toll

Benjamin Toll, Ph.D.

Associate Director, Education and Training

toll@musc.edu
Cannon Street 303B

Dr. Toll, a professor of public health sciences and psychiatry at MUSC, specializes in the treatment of tobacco use disorders and improvement of health behaviors. As associate director, his goal is to provide well-structured and effective education and training opportunities for pre- and post-doctoral students and junior faculty at Hollings Cancer Center.

 

Clinical Trials Leadership

Dr. David Marshall

David Marshall, M.D.

Clinical Trials Office Medical Director

marshadt@musc.edu

As a senior clinical investigator, Dr. Marshall leads the Hollings clinical trials office and mentors Hollings investigators to support the growth and high-performance of Hollings clinical trials. As the chair of Radiation Oncology, contact PI for the NCI Minority/Underserved Community Oncology Research Program (NCORP-MU), and with a decade of service on the IRB, Dr. Marshall helps integrate clinical and research activities within MUSC and MUSC's statewide partners.

 

Tricia Bentz

Tricia Bentz, MHA

Clinical Trials Office Administrative Director

adraleta@musc.edu

Bentz oversees the Hollings clinical trials office which provides centralized clinical, regulatory and financial support services to Hollings investigators. She leads initiatives to expand patient access to innovative cancer clinical trials and promote high quality assurance and clinical research education services. She obtained her masters in health administration and health information management and has over 20 years of oncology research experience.

 

Hollings Cancer Network

Jason Newman

Jason Newman, M.D.

Chief, Hollings Cancer Network
Head & Neck Cancer Division Director

newmajas@musc.edu

Dr. Newman leads the strategic growth of cancer programs across the state for Hollings. The expansion of clinical care, research and clinical trials makes innovative treatments more accessible for more patients and helps Hollings reach populations in rural and underserved areas. As the network grows, regional teams will be able to deliver care to patients locally with specialized treatment available in Charleston.

 

Kevin Plate

Kevin Platé, MBA

System Administrative Officer
Associate Director, Clinical Services

plate@musc.edu
Hollings Cancer Center 118E

Platé is responsible for driving oncology ICCE strategy, oversight of day-to-day clinical oncology operations, performance and growth of oncology clinical services and ensuring academic integration. Prior to joining MUSC, Platé worked for 18 years at Atrium Health in Charlotte, NC, in various leadership roles. In 2010, he joined the administrative team at Atrium’s Levine Cancer Institute and developed their cancer network across North and South Carolina.

 

Laura Sample

Laura Sample, MHA, FACHE

Oncology Network Administrator

samplel@musc.edu
Hollings Cancer Center 118F

As the Oncology Network Administrator, Sample is leading the efforts to expand cancer services throughout South Carolina. She comes to MUSC from Duke University Health System, where she brings 15+ years of experience in oncology, strategy and business development.